Episode 215  |  27:22 min  |  06.21.2021

How RADx Tech II Program is Fast-Tracking COVID-19 Technologies to Market in 2021

00:00
00:00
This is a podcast episode titled, How RADx Tech II Program is Fast-Tracking COVID-19 Technologies to Market in 2021. The summary for this episode is: <p>What can you still do to help in response to the COVID-19 pandemic? The National Institute of Biomedical Imaging and Bioengineering (NIBIB) announced that its Point-of-Care Technology Research Network (POCTRN) is soliciting proposals to further advance SARS-CoV-2 testing technologies to fill specific unmet national needs through RADx Tech II, a fast-track program that leverages POCTRN.</p><p>In this episode of the Global Medical Device Podcast Jon Speer talks to Mark Marino, Vice President of Growth and Strategy Development at VentureWell. VentureWell has been involved with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Program. </p><p>Listen to this episode to learn more about the RADx Tech II program to fast-track eligible technologies to market in 2021.</p><h3><strong style="color: rgb(67, 67, 67); background-color: transparent;">Some highlights of this episode include:</strong></h3><ul><li><span style="background-color: transparent;">Under this RADx Tech II solicitation, NIBIB is seeking proposals to accelerate validation, manufacturing scale up, and commercialization of innovative COVID-19 testing capabilities.</span></li><li><span style="background-color: transparent;">Capabilities include the full range of COVID testing from antigen to labs and POC to over-the-counter (OTC).</span></li><li><span style="background-color: transparent;">Mark is starting to see some rapid evolution with some exciting technologies that are starting to come up in the pipeline of the market.</span></li><li><span style="background-color: transparent;">It’s unfortunate that it took COVID-19 to spark innovation and acceleration of bringing products and technologies to the market.</span></li><li><span style="background-color: transparent;">Unmet needs still exist, particularly when it comes to screening, surveillance, diagnostics, and prognosis related to at-home and point of care tests.</span></li><li><span style="background-color: transparent;">How are tests holding up to variants? Adjust and modify tests to be as fast and responsive to address variant capabilities.</span></li><li><span style="background-color: transparent;">RADx Tech I versus Tech II programs will follow a similar phased-based approach for funding, infrastructure, and other systems. Less data is needed, but the data still needs to hold up.</span></li></ul><h3><strong style="color: rgb(67, 67, 67); background-color: transparent;">Memorable Quotes from Mark Marino:</strong></h3><p><em style="color: rgb(0, 0, 0); background-color: transparent;">“It’s labs, point of care, it’s antigen, it’s over-the-counter, really the full-range of COVID testing.”</em></p><p><em style="color: rgb(0, 0, 0); background-color: transparent;">“Now, we’re really starting to see some really rapid evolution with some really exciting technologies that are starting to come up in the pipeline of the market.”</em></p><p><em style="color: rgb(0, 0, 0); background-color: transparent;">“Everyone kind of knows, everyone has an expertise. Everyone has the same goal. People are letting go of both ego and showing up with tons of humility about what can I do to help? How can I add value?”</em></p><p><em style="color: rgb(0, 0, 0); background-color: transparent;">“We still understand that there are some unmet needs, particularly when it comes to screening, surveillance, diagnostics, and prognosis related to at-home and point of care tests.”</em></p><h3><strong style="color: rgb(67, 67, 67); background-color: transparent;">Links:</strong></h3><p><a href="https://www.linkedin.com/in/markangelomarino/" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">Mark Marino - LinkedIn</a></p><p><a href="https://www.poctrn.org/radx-tech-2" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">RADx Tech II - POCTRN - CIMIT</a></p><p><a href="https://venturewell.org/" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">VentureWell Home Page - Welcome to VentureWell</a></p><p><a href="https://www.nih.gov/" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">National Institutes of Health (NIH)</a></p><p><a href="https://www.nibib.nih.gov/" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">National Institute of Biomedical Imaging and Bioengineering (NIBIB)</a></p><p><a href="https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">FDA - Emergency Use Authorization (EUA)</a></p><p><a href="https://www.history.com/topics/world-war-ii/the-manhattan-project#:~:text=The%20Manhattan%20Project%20was%20the,weapon%20during%20World%20War%20II.&amp;text=The%20Manhattan%20Project%20was%20started,was%20prepared%20to%20use%20it." rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">The Manhattan Project</a></p><p><a href="https://www.greenlight.guru/academy" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">Greenlight Guru Academy</a></p><p><a href="https://virtual-summit.greenlight.guru/" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">The Greenlight Guru True Quality Virtual Summit</a></p><p><a href="https://www.greenlight.guru/podcast-mtqs" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">MedTech True Quality Stories Podcast</a></p><p><a href="https://www.youtube.com/channel/UCYfQsPqHW8H8mZ4xpM4gn1Q" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">Greenlight Guru YouTube Channel</a></p><p><a href="https://www.greenlight.guru/" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">Greenlight Guru</a></p>

What can you still do to help in response to the COVID-19 pandemic? The National Institute of Biomedical Imaging and Bioengineering (NIBIB) announced that its Point-of-Care Technology Research Network (POCTRN) is soliciting proposals to further advance SARS-CoV-2 testing technologies to fill specific unmet national needs through RADx Tech II, a fast-track program that leverages POCTRN.

In this episode of the Global Medical Device Podcast Jon Speer talks to Mark Marino, Vice President of Growth and Strategy Development at VentureWell. VentureWell has been involved with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Program.

Listen to this episode to learn more about the RADx Tech II program to fast-track eligible technologies to market in 2021.

Some highlights of this episode include:

  • Under this RADx Tech II solicitation, NIBIB is seeking proposals to accelerate validation, manufacturing scale up, and commercialization of innovative COVID-19 testing capabilities.
  • Capabilities include the full range of COVID testing from antigen to labs and POC to over-the-counter (OTC).
  • Mark is starting to see some rapid evolution with some exciting technologies that are starting to come up in the pipeline of the market.
  • It’s unfortunate that it took COVID-19 to spark innovation and acceleration of bringing products and technologies to the market.
  • Unmet needs still exist, particularly when it comes to screening, surveillance, diagnostics, and prognosis related to at-home and point of care tests.
  • How are tests holding up to variants? Adjust and modify tests to be as fast and responsive to address variant capabilities.
  • RADx Tech I versus Tech II programs will follow a similar phased-based approach for funding, infrastructure, and other systems. Less data is needed, but the data still needs to hold up.

Memorable Quotes from Mark Marino:

“It’s labs, point of care, it’s antigen, it’s over-the-counter, really the full-range of COVID testing.”

“Now, we’re really starting to see some really rapid evolution with some really exciting technologies that are starting to come up in the pipeline of the market.”

“Everyone kind of knows, everyone has an expertise. Everyone has the same goal. People are letting go of both ego and showing up with tons of humility about what can I do to help? How can I add value?”

“We still understand that there are some unmet needs, particularly when it comes to screening, surveillance, diagnostics, and prognosis related to at-home and point of care tests.”

Links:

Mark Marino - LinkedIn

RADx Tech II - POCTRN - CIMIT

VentureWell Home Page - Welcome to VentureWell

National Institutes of Health (NIH)

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

FDA - Emergency Use Authorization (EUA)

The Manhattan Project

Greenlight Guru Academy

The Greenlight Guru True Quality Virtual Summit

MedTech True Quality Stories Podcast

Greenlight Guru YouTube Channel

Greenlight Guru

More Episodes

eQMS in Academia: Practical Learning for Biomedical Engineering Students

Tips for Running Better Management Reviews

Meet a Guru: Ryan Behringer

Navigating the MedTech Cybersecurity Ecosystem

Managing Clinical Data Activities

Explaining the Role of Importer under EU MDR